Using DNA to detect liver cancer return
Part of Cancer, Digestive system clinical trials.
This trial uses a blood test to check for signs of liver cancer coming back after treatment. It may help find recurrence earlier than standard scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer.
- You do not have any other active cancer.
- You are eligible for surgery, transplant, ablation, or a treatment called TACE.
- You have a positive result on a DNA methylation test before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new blood test that looks for DNA from cancer cells' mitochondria to see if it can catch liver cancer coming back earlier. The goal is to help doctors find recurrence faster and improve follow-up care.
This trial studies a new blood test that looks for bits of tumor DNA (ct-mtDNA) to see if it can detect if biliary tract cancer has come back earlier than standard scans. The test might help doctors monitor for recurrence more closely.
This study is testing a new gene test (GNB4 and Riplet) to monitor liver cancer patients for possible return of cancer after treatment. It is designed for people who have liver cancer and are having surgery, transplant, ablation, or TACE treatment.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
This trial is for people with early-stage liver cancer who are scheduled for surgery. It uses a simple blood test to look for tiny bits of tumor DNA after treatment, which may help predict if the cancer will come back.
This study checks whether a blood test that looks for leftover cancer DNA (ctDNA) after surgery can predict if your liver cancer will come back. It compares that test result with what doctors find in the removed tumor tissue.
Hear when a new Primary Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.